Alpine Immune Sciences (STU:34LA) Net Change in Cash : €27.86 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Alpine Immune Sciences's Net Change in Cash for the three months ended in Dec. 2023 was €22.88 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was €27.86 Mil.

Alpine Immune Sciences Net Change in Cash Historical Data

The historical data trend for Alpine Immune Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Net Change in Cash Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

5.10

15.38

29.16

-51.48

28.02

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-106.91	1.02	18.10	-14.14	22.88

Alpine Immune Sciences Net Change in Cash Calculation

Alpine Immune Sciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-72.454	+	-50.948	+	151.417	+	0.007
	=	28.02

Alpine Immune Sciences's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -17.396 + -103.348 + 143.611 + 0.016

= 22.88

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpine Immune Sciences Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Alpine Immune Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (STU:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Net Change in Cash

Comparable Companies

VERA ZYME AUTL TBPH TYRA ELVN SVRA ARCT ALLO TARS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ALPN:USA

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines